Absence of BRAF V600E in non-infiltrative, non-invasive follicular variant of papillary thyroid carcinoma

2015 ◽  
Vol 67 (4) ◽  
pp. 579-582 ◽  
Author(s):  
Brooke E Howitt ◽  
Vera A Paulson ◽  
Justine A Barletta
Keyword(s):  
Papillary Thyroid Carcinoma ◽  
Thyroid Carcinoma ◽  
Braf V600e ◽  
Papillary Thyroid ◽  
Follicular Variant ◽  
Non Invasive

scholarly journals Outcome and molecular characteristics of non-invasive encapsulated follicular variant of papillary thyroid carcinoma with oncocytic features

Endocrine ◽  
2019 ◽  
Vol 64 (1) ◽  
pp. 97-108 ◽  
Author(s):  
Bin Xu ◽  
Ed Reznik ◽  
R. Michael Tuttle ◽  
Jeffrey Knauf ◽  
James A. Fagin ◽  
...  
Keyword(s):  
Papillary Thyroid Carcinoma ◽  
Thyroid Carcinoma ◽  
Molecular Characteristics ◽  
Papillary Thyroid ◽  
Follicular Variant ◽  
Non Invasive

scholarly journals Preoperative RAS Mutational Analysis Is of Great Value in Predicting Follicular Variant of Papillary Thyroid Carcinoma

2015 ◽  
Vol 2015 ◽  
pp. 1-8 ◽  
Author(s):  
Tae Sook Hwang ◽  
Wook Youn Kim ◽  
Hye Seung Han ◽  
So Dug Lim ◽  
Wan-Seop Kim ◽  
...  
Keyword(s):  
Papillary Thyroid Carcinoma ◽  
Thyroid Carcinoma ◽  
Thyroid Nodules ◽  
Mutational Analysis ◽  
Braf V600e ◽  
Papillary Thyroid ◽  
Follicular Variant ◽  
Ras Mutation ◽  
Ras Mutations ◽  
Codon 61

Follicular variant of papillary thyroid carcinoma (FVPTC), particularly the encapsulated subtype, often causes a diagnostic dilemma. We reconfirmed the molecular profiles in a large number of FVPTCs and investigated the efficacy of the preoperative mutational analysis in indeterminate thyroid nodules. BRAF V600E/K601E and RAS mutational analysis was performed on 187 FVPTCs. Of these, 132 (70.6%) had a point mutation in one of the BRAF V600E (n=57), BRAF K601E (n=11), or RAS (n=64) genes. All mutations were mutually exclusive. The most common RAS mutations were at NRAS codon 61. FNA aspirates from 564 indeterminate nodules were prospectively tested for BRAF and RAS mutation and the surgical outcome was correlated with the mutational status. Fifty-seven and 47 cases were positive for BRAF and RAS mutation, respectively. Twenty-seven RAS-positive patients underwent surgery and all except one patient had FVPTC. The PPV and accuracy of RAS mutational analysis for predicting FVPTC were 96% and 84%, respectively. BRAF or RAS mutations were present in more than two-thirds of FVPTCs and these were mutually exclusive. BRAF mutational analysis followed by N, H, and KRAS codon 61 mutational analysis in indeterminate thyroid nodules would streamline the management of patients with malignancies, mostly FVPTC.

Molecular genotyping of the non-invasive encapsulated follicular variant of papillary thyroid carcinoma

2017 ◽  
Vol 72 (4) ◽  
pp. 648-661 ◽  
Author(s):  
Tae Hyuk Kim ◽  
Minju Lee ◽  
Ah-Young Kwon ◽  
Jun-Ho Choe ◽  
Jung-Han Kim ◽  
...  
Keyword(s):  
Papillary Thyroid Carcinoma ◽  
Thyroid Carcinoma ◽  
Papillary Thyroid ◽  
Follicular Variant ◽  
Molecular Genotyping ◽  
Non Invasive

Impact of the Reclassification of the Non-Invasive Follicular Variant of Papillary Carcinoma as Benign on the Malignancy Risk of the Bethesda System for Reporting Thyroid Cytopathology: A Meta-Analysis Study

2017 ◽  
Vol 61 (3) ◽  
pp. 187-193 ◽  
Author(s):  
Lester J. Layfield ◽  
Zubair W. Baloch ◽  
Magda Esebua ◽  
Rohini Kannuswamy ◽  
Robert L. Schmidt
Keyword(s):  
Papillary Thyroid Carcinoma ◽  
Thyroid Carcinoma ◽  
Meta Analysis ◽  
Papillary Thyroid ◽  
Follicular Variant ◽  
Malignancy Risk ◽  
Diagnostic Categories ◽  
Non Invasive ◽  
Thyroid Cytopathology ◽  
The Bethesda System

Objectives: The Bethesda System for Reporting Thyroid Cytopathology (TBSRTC) established diagnostic categories for cytologic specimens of the thyroid. Each category was associated with an estimated risk of malignancy. Recently, the non-invasive follicular variant of papillary thyroid carcinoma has been reclassified as benign. This reclassification may alter the malignancy risk of TBSRTC diagnostic categories. Study Design: A literature search was made for all studies investigating the effect of reclassification of some non-invasive follicular variant papillary thyroid carcinomas as benign on the malignancy risk associated with TBSRTC categories. The authors calculated the malignancy risk for TBSRTC categories in a series of 315 thyroid aspirates when the non-invasive follicular variant of papillary thyroid carcinoma was considered benign. A meta-analysis of malignancy risk data for the 3 published studies and the current study was performed. Results: The meta-analysis showed that the malignancy risk was reduced for all TBSRTC categories except the “non-diagnostic” category. The reduction in malignancy risk was greatest in the categories “suspicious for malignancy” and “atypia/follicular lesion of undetermined significance.” Conclusion: A meta-analysis of all pertinent studies demonstrated that re-categorization of the non-invasive follicular variant of papillary thyroid carcinoma as benign reduces the malignancy risk in the majority of TBSRTC categories.

scholarly journals Should subcentimeter non-invasive encapsulated, follicular variant of papillary thyroid carcinoma be included in the noninvasive follicular thyroid neoplasm with papillary-like nuclear features category?

Endocrine ◽  
2017 ◽  
Vol 59 (1) ◽  
pp. 143-150 ◽  
Author(s):  
Bin Xu ◽  
Nada Farhat ◽  
Justine A. Barletta ◽  
Yin P. Hung ◽  
Dario de Biase ◽  
...  
Keyword(s):  
Papillary Thyroid Carcinoma ◽  
Thyroid Carcinoma ◽  
Thyroid Neoplasm ◽  
Papillary Thyroid ◽  
Follicular Variant ◽  
Non Invasive ◽  
Nuclear Features

scholarly journals Cytologic, histologic and molecular findings of papillary thyroid carcinoma variants, one institution’s experience

2019 ◽  
Vol 9 (2) ◽  
pp. 32
Author(s):  
Nadja K. Falk ◽  
Swarnamala Ratnayaka ◽  
Andrew Sholl ◽  
Krzysztof Moroz ◽  
Tatyana Kalinicheva
Keyword(s):  
Papillary Thyroid Carcinoma ◽  
Thyroid Carcinoma ◽  
Braf V600e ◽  
Papillary Thyroid ◽  
Follicular Variant ◽  
Tert Promoter Mutations ◽  
Patient Prognosis ◽  
One Year ◽  
Promoter Mutations ◽  
Worse Prognosis

Papillary thyroid carcinoma (PTC) has two major types, classic (PTCC) and follicular variant (FVPTC), which correlate with molecular findings and have varying clinical implications. We assessed the cytologic findings and subsequent surgical pathology findings with the molecular mutations in these two groups, including microcarcinomas. Fourty-four patients with PTC resections over a one-year period were retrospectively examined in conjunction with previous cytologic diagnoses. BRAF, NRAS and TERT promoter mutations for the resected specimens were analyzed. Correlation with previous cytology in regard to molecular mutations and tumor size (microcarcinoma) were made. Significantly more BRAF V600E mutations were seen with PTCC, whereas significantly more NRAS mutations were seen with FVPTC. TERT mutations were only seen with PTCC. Molecular studies for thyroid carcninomas are becoming increasingly more common and influence treatment and patient prognosis. BRAF and or TERT mutations are associated with a worse prognosis. NRAS mutations associated with FVPTC and may lead to milder cytologic changes compared to the BRAF- and TERT-driven PTCC.

Sign in / Sign up

Export Citation Format

Share Document